Previous studies have demonstrated the limited permeability of an intact blood–brain barrier [10–12]. However with the presence of tumor cells the BBB becomes heterogeneously disrupted and has been noted as the blood-tumor barrier (BTB) . The BTB and BBB provide a physical barrier with collaborative cells that inhibit entry of toxins, including chemotherapy. Specifically, the BTB amongst malignant gliomas is unique with a high proliferative index of microvasculature and evident alterations in astrocytic endfeet and transcytotic mechanisms; making the BTB more leaky in certain areas of the tumor but peritumoral brain less permeable with a normal BBB [10, 13–15]. These factors collectively play a role in restricting drug entry and have guided extensive research on how best to enhance transport to the CNS.